TABLE II.
Prevalence of Genotypic-Resistance Mutations Among Drug-Naïve HIV-1 Non-B Subtype Infected Patients
| Patient ID | Age | Sex | Viral load copies/ml | Genotypic-resistance mutations | High-level drug resistancea | RT subtype | ||
|---|---|---|---|---|---|---|---|---|
| NRTI | NNRTI | NRTI | NNRTI | |||||
| 06ARC004 | 35 | M | 8,358 | None | None | — | — | CRF02_AG |
| 06ARC010 | 30 | F | 14,715 | None | None | — | — | CRF02_AG |
| 06ARC013 | 31 | F | 1,823 | None | None | — | — | U |
| 06ARC076 | 33 | F | 3,649 | K65R | K101E | — | — | F2 |
| 06BDHS019 | 28 | F | <75 | None | None | — | — | U |
| 06BDHS020 | 30 | F | 93 | None | None | — | — | CRF02_AG |
| 06BDHS023 | 38 | F | 293 | None | None | — | — | CRF13_cpx |
| 06BDHS024 | 27 | F | 1,400 | M184V | V1081, Y181C | 3TC, FTC | NVP, DLV | F2 |
| 06BDHS028 | 31 | M | 511 | M184V | K103N | 3TC, FTC | NVP, DLV, EFV | CRF02_AG |
| 06BDHS035 | 29 | F | 1,604 | None | None | — | — | CRF02_AG |
| 07BDHS053 | 28 | M | 38,442 | None | None | — | — | A |
| 07BDHS054 | 29 | M | 185 | None | G190A | — | — | CRF02_AG |
| 07BDHS055 | 27 | F | 3,368 | None | None | — | — | CRF02_AG |
| 06LPH01OJ | 36 | M | 4,401 | None | None | — | — | U |
| 06LPH02MG | 35 | F | 141,198 | None | None | — | — | CRF02_AG |
| 06LPH03VJ | 52 | M | 25,517 | None | None | — | — | CRF02_AG |
| 06LPH05DE | 48 | F | 15,135 | None | None | — | — | CRF02_AG |
| 06LPH11TT | 27 | F | <75 | None | None | — | — | A |
| 06LPH21ZC | 29 | M | 1,629 | None | None | — | — | CRF02_AG |
| 06LPH22NH | 31 | F | 292,627 | None | None | — | — | CRF02_AG |
| 06LPH19CM | 18 | F | 31,557 | None | None | — | — | A |
RT, reverse transcriptase.
a
Stanford University HIV Drug-Resistance Database, interpretation of NRTI and NNRTI-resistance mutations (susceptible-, low-, and intermediate-level of drug resistance not shown).